-
Bayer Pharma AG et al v. Watson Laboratories Inc. DC CAFC
- 1:12-cv-01726
- D. Del.
- Judge: Leonard P. Stark
- Filed: 12/18/2012
- Closed: 12/28/2016
- Latest Docket Entry: 08/10/2018
- PACER
3
Plaintiffs
2
Defendants
1
Accused
Product
1
Patent-in-Suit
1,472
Days in
Litigation
-
Bayer Pharma AG et al v. Watson Laboratories Inc. DC CAFC
- 1:12-cv-01726
- D. Del.
- Judge: Leonard P. Stark
- Filed: 12/18/2012
- Closed: 12/28/2016
- Latest Docket Entry: 08/10/2018
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A multiphase product for contraception comprising: a first phase of 2 daily dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily dosage units, a first group comprising 5 daily dosage units, each of which
view more
|
Valid (101 and 102 and 103 and 112)
Entry 173 Entry 166 |
2 |
A multiphase oral contraception product comprising: a first phase of 2 daily oral dosage units, each comprising 3 mg of estradiol valerate, a second phase of 2 groups of daily oral dosage units, a first group comprising 5 daily oral dosage units,
view more
|
Valid (101 and 102 and 103 and 112)
Entry 173 Entry 166 |
3 |
A method of oral contraception comprising orally administering to a woman: one oral dosage unit comprising 3 mg of estradiol valerate daily for 2 days, then one oral dosage unit comprising 2 mg of estradiol valerate and 2 mg of dienogest daily for 5
view more
|
Valid (101 and 102 and 103 and 112)
Entry 173 Entry 166 |
-
Infringement
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Nataziageneric version of Natazia | US 8,071,577 B2 |
1, 2, 3
|
Infringement
Entry 173Entry 166 Entry 165 |
Watson Pharmaceuticals, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Natazia | US 8,071,577 B2 |
1, 2, 3
|
Infringement
Entry 165
|